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WELCOME TO THE WORLD OF 
TOMORROW: AN EXPLORATION OF CELL-
BASED MEATS AND HOW THE FDA AND 
USDA MAY PROTECT INTELLECTUAL 
PROPERTY RIGHTS 
Sean Anthony Grafton* 
As the accumulation of greenhouse gases continues to cause the Earth to 
warm,1 as the population continues to grow at an exponential rate causing food 
shortage concerns,2 and as pollution of the Earth’s waterways continues to cause 
growing concerns of clean water shortages,3 scientists continue to find new ways 
to address these issues. After years of stem cell research, scientists have started 
to address these issues by creating lab-grown meats, also known as cell-based 
meats.4 
                                                          
* Sean Grafton is a recently barred Washington, D.C. attorney with a background in genetic 
research. He currently works for the United States Court of Federal Claims as a law clerk. 
During law school, Sean interned for the U.S. Environmental Protection Agency Office of 
Enforcement and Compliance Assurance (“OECA”) where he helped lead a multi-
department investigation of a major water polluter. Previously, Sean has worked in genetic 
labs at both the Ohio State University and the University of Michigan. Using his science 
background, he hopes to continue his career in the biotechnology and drug legal space 
where he can bring his expertise in both fields together to effect positive change. He 
graduated cum laude from the Catholic University of America, Columbus School of Law in 
2019 and from Bowling Green State University in 2010. 
 
 1 Climate Change: How Do We Know?, NASA, https://climate.nasa.gov/evidence/ (last 
visited Apr. 10, 2020). 
 2 Joseph Hincks, The World Is Headed for a Food Security Crisis. Here’s How We Can 
Avert It, TIME (Mar. 28, 2018), http://time.com/5216532/global-food-security-richard-
deverell/. 
 3 Stephen Leahy, From Not Enough to Too Much, the World’s Water Crisis Explained, 
NAT’L GEOGRAPHIC (Mar. 22, 2018), https://news.nationalgeographic.com/2018/03/world-
water-day-water-crisis-explained/. 
 4 Mark J. Post, An Alternative Animal Protein Source: Cultured Beef, ANNALS N.Y. 
ACAD. SCI., Nov. 2014, at 29, 30. 
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Cell-based meats are meats grown using muscle tissues and stem cells in 
laboratory conditions.5 Eventually, those stem cells grow into muscle fibers that 
resemble and taste like the meats they are derived from.6 It is generally accepted 
that these types of meats are called cell-based meats, but they also go by names 
such as clean meat, artificial meat, cultured meat, or cultured tissue.7 
Despite sounding like science fiction, the idea of growing meat in a laboratory 
setting has held a special place in the public imagination. In 1931, Winston 
Churchill wrote, “We shall escape the absurdity of growing a whole chicken in 
order to eat the breast or wing, by growing these parts separately under a suitable 
medium.”8 Cultivation of muscle tissue was shown to be successful as early as 
1971 by Russell Ross.9 Ross reported that, “Smooth muscle derived from the 
inner media and intima of immature guinea pig aorta were grown for up to 8 
weeks in cell culture[s].”10 
Cell-based meats are soon coming to grocery stores all around the country.11 
As cell-based meats get closer to coming to market, there will be serious 
questions raised as to how to protect intellectual property (“IP”) rights related to 
cell lines,12 how to protect IP rights related to growth processes,13 and which 
government agency will regulate this area of the market.14 
Part I of this Comment will discuss the general background of stem cells and 
                                                          
 5 G. Owen Schaefer, Lab-Grown Meat, SCI. AM. (Sept. 14, 2018), 
https://www.scientificamerican.com/article/lab-grown-meat/. 
 6 Id. 
 7 Sarah Zhang, The Farcical Battle over What to Call Lab-Grown Meat, THE ATLANTIC 
(July 13, 2018), https://www.theatlantic.com/science/archive/2018/07/lab-grown-
meat/565049/; Jamie Mah, Plant and Cell Based Meat, Explained, MEDIUM (Feb. 7, 2019), 
https://medium.com/track-and-food/plant-and-cell-based-meat-explained-6c09dedad041. 
 8 Paul Shapiro, Commentary: Science Fiction No More, Can Lab-Grown Meat Feed—
and Save—the World?, REUTERS (Feb. 26, 2018), https://www.reuters.com/article/us-
shapiro-meat-commentary/commentary-science-fiction-no-more-can-lab-grown-meat-feed-
and-save-the-world-idUSKCN1GA25H. 
 9 See generally Russell Ross, The Smooth Muscle Cell: II. Growth of Smooth Muscle in 
Culture and Formation of Elastic Fibers, 50 J. CELL BIOLOGY 172, 172 (1971). 
 10 Id. 
 11 Jade Scipioni, Lab-Grown Meat Coming to Supermarket Shelves Soon?, FOX BUS. 
(May 1, 2017), https://www.foxbusiness.com/features/lab-grown-meat-coming-to-
supermarket-shelves-soon. 
 12 Josephine Johnston, Intellectual Property and Biomedicine, HASTINGS CTR., 
https://www.thehastingscenter.org/briefingbook/intellectual-property-and-biomedicine/ (last 
visited Apr. 10, 2020). 
 13 Chandra Nath Saha & Sanjib Bhattacharya, Intellectual Property Rights: An 
Overview and Implications in Pharmaceutical Industry, 2 J. ADVANCED PHARMACEUTICAL 
TECH. & RES. 88, 89 (2011). 
 14 Kelsey Piper, The Lab-Grown Meat Industry Just Got the Regulatory Oversight It’s 
Been Begging For, VOX (Mar. 9, 2019, 8:00 AM), https://www.vox.com/future-
perfect/2019/3/9/18255806/fda-usda-lab-grown-meat-cell-based-vegan-vegetarian. 
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how cell-based meats are grown. Next, Part II will discuss the implications of 
lab-grown meats in the world, including environmental impacts, social impacts, 
and the effects on animal-rights movements. Part III will discuss how some of 
the states that rely on traditional agriculture have responded to cell-based meats 
coming to market. Then, Part IV will continue with an explanation of the prior 
law of IP rights, cell rights, and expected Food and Drug Administration 
(“FDA”) and United States Department of Agriculture (“USDA”) joint 
regulation of cell-based meats. This part will also include a primer on the Hatch-
Waxman laws. Part V will discuss some of the loopholes created by the Hatch-
Waxman Act that will need to be addressed if new legislation is enacted to deal 
with cell-based meats. Part VI will compare the FDA and USDA laws and 
explain how the growing processes of lab-grown meats may find IP protections 
the same way generic drugs have found protections through Hatch-Waxman. 
Finally, Part VII will summarize the arguments: the FDA should be given full 
regulatory authority in order to avoid undue delays in the patent process. 
This Comment explores how cell-based meats will be regulated by the FDA 
and the USDA, the current IP protections over the cells and growing processes, 
and how Congress can provide IP protections over the individual cell lines and 
the growing processes based on current IP frameworks in the generic drug world. 
The main focus of this Comment will be how Congress could use the Hatch-
Waxman Act15 as a framework to create new IP protections for cell-based meats 
to give some additional IP protections to the companies producing cell-based 
meats. The FDA16 will share regulatory responsibility with the USDA based on 
initial conversations between the White House, FDA, and the USDA.17 
Specifically, the FDA will regulate the food safety side of the industry.18 The 
advantage of having the FDA involved in the regulation of cell-based meats is 
that the FDA already has a history of providing additional IP protections for 
drugs through the Hatch-Waxman Act.19 Thus, Congress should consider 
                                                          
 15 See 21 U.S.C. § 355 (2012). 
 16 USDA and FDA Announce a Formal Agreement to Regulate Cell-Cultured Food 
Products from Cell Lines of Livestock and Poultry, U.S. FOOD & DRUG ADMIN. (Mar. 7, 
2019), https://www.fda.gov/news-events/press-announcements/usda-and-fda-announce-
formal-agreement-regulate-cell-cultured-food-products-cell-lines-livestock-and. 
 17 Wyatt Bechtel, Joint Letter Sent to President Trump on Lab-Grown Meat 
Regulations, DROVERS (Aug. 23, 2018), https://www.drovers.com/article/joint-letter-sent-
president-trump-lab-grown-meat-regulations. 
 18 Formal Agreement Between FDA and USDA Regarding Oversight of Human Food 
Produced Using Animal Cell Technology Derived from Cell Lines of USDA-Amenable 
Species, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/food/domestic-interagency-
agreements-food/formal-agreement-between-fda-and-usda-regarding-oversight-human-
food-produced-using-animal-cell (last updated Mar. 7, 2019) [hereinafter Formal 
Agreement]. 
 19 See 21 U.S.C. § 355 (2012). 
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passing an act similar to Hatch-Waxman in the cell-based meat arena to help 
implement IP protections over the cell-based meat growing processes as 
companies wait for approval from the FDA and the USDA. Similar to drug 
companies jumping into the generic drugs market after a successful showing of 
the brand drug, there will be an increasing number of companies trying to enter 
the cell-based meat market.20 Congress will need to address the issues of 
competition and IP rights before it creates a backlog in the courts,21 or a few 
companies create monopolies.22 The framework of the Hatch-Waxman Act 
provides a practical example of how to do this moving forward. 
I. BACKGROUND OF STEM CELLS AND CELL-BASED MEATS 
A. The Science of Stem Cells 
The science of stem cells has been studied and understood for a long time.23 
Stem cells are pervasive in all living things and among all types of cells and 
tissues.24 In the simplest sense, stem cells are the cells that have yet to 
differentiate into specific cells or tissues.25 These cells are influenced by the 
surrounding cells and have demonstrated the surprising ability to transform into 
other tissues and cell types.26 Eventually, these stem cells can become muscle 
tissue, skin, or red blood cells.27 Stem cells are the building blocks of the human 
body and how the body renews itself.28 
There are a few different types of stem cells including embryonic,29 
                                                          
 20 Jessi Devenyns, Cell-Based Food Maker New Age Meats Raises $2.7M in Funding, 
FOOD DIVE (Jan. 13, 2020), https://www.fooddive.com/news/cell-based-food-maker-new-
age-meats-raises-27m-in-funding/570267/. 
 21 Lawrence Hurley, U.S. High Court Sets Record for Intellectual Property Caseload, 
REUTERS (Feb. 27, 2014), https://www.reuters.com/article/us-usa-court-ip-analysis/u-s-high-
court-sets-record-for-intellectual-property-caseload-idUSBREA1Q09B20140227. 
 22 Cultured Meat Market Leveraging the Environment Ramifications of Animal 
Agriculture, INDUSTRYARC (Aug. 26, 2019), 
https://www.industryarc.com/PressRelease/1749/Cultured-Meat-Market-Research.html. 
 23 The Adult Stem Cell, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/ 
2001report/chapter4.htm (last visited Apr. 10, 2020). 
 24 Stem Cell Basics IV, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/ 
basics/4.htm (last visited Apr. 10, 2020). 
 25 Stem Cell Basics I, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/ 
basics/1.htm (last visited Apr. 10, 2020). 
 26 David A. Prentice, Adult Stem Cells, 19 ISSUES L. & MED. 265, 265 (2004). 
 27 Stem Cell Basics I, supra note 25. 
 28 Stem Cell Basics II, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/ 
basics/1.htm (last visited Apr. 10, 2020). 
 29 Stem Cell Basics III, NAT’L INSTS. OF HEALTH, https://stemcells.nih.gov/info/ 
basics/1.htm (last visited Apr. 10, 2020). 
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pluripotent, chord,30 and hematopoietic stem cells;31 however, the stem cells 
used in growing cell-based meats are the specific animal’s adult stem cells.32 
Adult stem cells have certain special characteristics, such as the ability to 
duplicate themselves for long periods of time, which is referred to as long-term 
self-renewal.33 These particular stem cells give rise to mature cell types that have 
specialized functions after the cell duplicates and divides.34 The primary 
functions of adult stem cells are to maintain the job of a cell and to replace dead 
cells.35 
When creating cell-based meats in a laboratory, scientists take certain animal 
cells and place those cells in a blood-like growth medium with cells similar to 
their future self; after some time, the result is a product that both tastes like and 
functions the same as the meat it was harvested from.36 This is possible because 
the adult stem cells only know how to replicate the specific cells which they are 
programmed to become, regardless of whether they are in a living body or in a 
Petri dish in a lab.37 Scientists will do this for both the smooth muscle meat cells 
and the fat cells of an animal to create essentially the same product available 
every day in grocery stores.38 
B. Background of Cell-Based Meats 
Lab-grown meats are made through a process called “cellular agriculture.”39 
“Cellular agriculture is a method of agricultural production enabling the growth 
of meat, eggs, and leather in cell culture rather than raising and slaughtering 
livestock.”40 Researchers discovered this process after experimenting with 
animal stem cells.41 
                                                          
 30 Id. 
 31 Stem Cell Basics II, supra note 28. 
 32 Walter Johnson et al., Burgers Grown in a Lab Are Heading to Your Plate. Will You 
Bite?, WASH. POST (Sept. 9, 2018), https://www.washingtonpost.com/national/health-
science/burgers-grown-in-a-lab-are-heading-to-your-plate-will-you-bite/2018/09/07/ 
1d048720-b060-11e8-a20b-5f4f84429666_story.html?utm_term=.a5e08e698a86. 
 33 The Adult Stem Cell, supra note 23. 
 34 Id. 
 35 Id. 
 36 Shaefer, supra note 5. 
 37 Stem Cell Basics II, supra note 28. 
 38 Yaakov Nahmias, Lab-Grown Meat Is Getting Cheap Enough for Anyone to Buy, 
FAST COMPANY (May 2, 2018), https://www.fastcompany.com/40565582/lab-grown-meat-
is-getting-cheap-enough-for-anyone-to-buy. 
 39 Cell-Ag 101, CAS, https://www.cellag.org/cellag101/ (last visited Apr. 10, 2020). 
 40 Erin Kim, A Closer Look at Cellular Agriculture and the Processes Defining It, 
AGFUNDER (July 5, 2016), https://agfundernews.com/closer-look-cellular-agriculture-and-
the-processes-defining-it.html/. 
 41 Chase Purdy, The Idea for Lab-Grown Meat Was Born in a Prisoner-of-War Camp, 
QUARTZ (Sept. 24, 2017), https://qz.com/1077183/the-idea-for-lab-grown-meat-was-born-
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One of the first reported cultivations of muscle fibers was in 1971 after 
researchers grew guinea pig smooth heart muscle in Petri dishes.42 The United 
States National Aeronautics and Space Administration (“NASA”) immediately 
took an interest in cell-based meats so that its astronauts could have a source of 
protein during prolonged space trips.43 In 2002, NASA funded a research project 
focused on producing fish filets using cellular agriculture techniques.44 These 
fish filets were breaded and fried before they were presented to a food panel.45 
The panel commented that the cell-based fish sticks resembled and smelled like 
real fish filets; however, FDA regulations prevented the panel from performing 
a taste test because of health concerns.46 
After the NASA experiment, the Dutch government funded research on 
cultured meat from 2004 to 2009 and tasked Dr. Mark Post with leading the 
project.47 Although the initial project did not result in a huge breakthrough, Dr. 
Post continued his research independently after the Dutch government cut 
funding. 48 
In 2013, as a result of his research, Dr. Post was able to create and present the 
first cell-based burger at a highly publicized conference in London.49 The cell-
based burger was produced by “removing the stem cells from the shoulder 
muscle of a cow, growing them into thin strips of muscle in tissue culture flasks, 
and combining about 20,000 strips to make a burger.”50 Dr. Post displayed the 
world’s first cultured beef hamburger that “served as a proof of concept for this 
method, using established tissue engineering methods (the science of growing 
organs for human medical use) to grow the cow muscle cells that formed the 
beef patty.”51 As a result, “a small number of entrepreneurs are already 
                                                          
in-a-prisoner-of-war-camp/. 
 42 Ross, supra note 9, at 172. 
 43 Paul Shapiro, Lab-Grown Meat Is on the Way: It’s Good for the Planet, and Surveys 
Show that Significant Numbers of People Would Be Willing to Give It a Try, SCI. AM. (Dec. 
19, 2017), https://blogs.scientificamerican.com/observations/lab-grown-meat-is-on-the-
way/. 
 44 M.A. Benjaminson et al., In Vitro Edible Muscle Protein Production System (MPPS): 
Stage 1, Fish, 51 ACTA ASTRONAUTICA 879 (2002). 
 45 Maddie Stone, Meet the Radical Scientists Who Want to Grow Our Seafood in a Lab, 
GIZMODO (Feb. 9, 2016), https://gizmodo.com/meet-the-radical-scientists-who-want-to-
grow-our-seafoo-1752950596. 
 46 Laura Cassiday, Clean Meat, AOCS, https://www.aocs.org/stay-informed/read-
inform/featured-articles/clean-meat-february-2018 (last visited Apr. 10, 2020). 
 47 Id. 
 48 Id. 
 49 Id. 
 50 Id. 
 51 Kim, supra note 40. 
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embracing the science and launching startups like Memphis Meats,52 Muufri,53 
Clara Foods,54 Afineur,55 Meatable,56 and Gelzen.”57 
Dr. Post’s research spawned several startups that show the promise of creating 
a product that can be marketed.58 Meatable was created as a startup and has since 
been backed by both the University of Cambridge and Stanford University.59 
The company has secured over $3.5 million in seed money from these 
investors.60 Meatable has created cell lines of certain meats that will replicate 
themselves indefinitely, creating a process that may tackle the scalability and 
cost issues that accompany cell-based meats.61 
Memphis Meats is another cell-based meat startup that has benefited greatly 
from outside investing.62 Memphis Meats was founded in 2015 by a cardiologist 
and a cellular scientist.63 The startup created its first lab-grown meatball a year 
later and its first lab-grown poultry breast in March 2017.64 After its recent 
success, Memphis Meats will try to bring its products to market by 2021.65 
Memphis Meats has received substantial investments from both private and 
public sources.66 It has received Class A investments from the likes of Bill Gates, 
                                                          
 52 Home, MEMPHIS MEATS, https://www.memphismeats.com/ (last visited Apr. 16, 
2020). 
 53 How It Works, PERFECT DAY FOODS, https://www.perfectdayfoods.com/ (last visited 
Apr. 16, 2020). 
 54 Home, CLARA FOODS, https://www.clarafoods.com/ (last visited Apr. 16, 2020). 
 55 Home, AFINEUR, https://www.afineur.com/ (last visited Apr. 16, 2020). 
 56 Home, MEATABLE, https://www.meatable.com/ (last visited Apr. 16, 2020); see 
Catherine Lamb, Meatable Claims to Hold the Key to Scalable Cultured Meat in a Single 
Cell, SPOON (Oct. 5, 2018), https://thespoon.tech/meatable-claims-to-hold-the-key-to-
scalable-cultured-meat-in-a-single-cell/. 
 57 About Us, GELTOR, http://geltor.com/ (last visited Apr. 16, 2020); Kim, supra note 
40. 
 58 Kim, supra note 40. 
 59 Jessica Hasson, Meatable to Feed the World with Breakthrough Single-Cell-Based 
Meat Technology, GLOBE NEWSWIRE (Sept. 30, 2018), https://www.globenewswire.com/ 
news-release/2018/09/30/1587407/0/en/Meatable-to-Feed-the-World-with-Breakthrough-
Single-Cell-based-Meat-Technology.html. 
 60 Id. 
 61 Id. 
 62 Memphis Meats Raises $161 Million for Cell-Based Meat, RED HERRING (Jan. 24, 
2020), https://www.redherring.com/top-story/memphis-meats-raises-161-million-for-cell-
based-meat/. 
 63 About, MEMPHIS MEATS, https://www.memphismeats.com/about (last visited Jan. 26, 
2020). 
 64 Id. 
 65 Jon Card, Lab-Grown Food: “The Goal Is to Remove the Animal from Meat 
Production”, GUARDIAN (July 24, 2017), https://www.theguardian.com/small-business-
network/2017/jul/24/lab-grown-food-indiebio-artificial-intelligence-walmart-vegetarian. 
 66 Elie Dolgin, Sizzling Interest in Lab-Grown Meat Belies Lack of Basic Research, 
NATURE (Feb. 6, 2019), https://www.nature.com/articles/d41586-019-00373-w. 
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Cargill, and Richard Branson.67 More recently, it received a very large 
investment from Tyson.68 The company has raised over $17 million in series A 
funding as of the end of 2017.69 These investors have been outspoken in their 
support for lab-grown meats.70 Most of the support touted by these investors 
stems from the hope that this new technology will help end world hunger, be 
more environmentally friendly than current agricultural processes, and curve 
adverse livestock treatment.71 
II. IMPLICATIONS OF CELL-BASED MEATS FOR THE WORLD 
There is a lot of excitement behind new cell-based meat technology. Much of 
the excitement behind this technology is tied to the belief that it may solve the 
world food crisis.72 This is because the labs that grow the meat do not require 
much space to operate.73 Unlike farms that need space for animal grazing, 
milking, and slaughtering, lab-grown meats only need the lab and an area for 
harvesting.74 Thus, the physical footprint of agriculture can be reduced wherever 
these labs are located. In addition, these labs can be placed in areas that do not 
traditionally support livestock.75 
Part of the world food crisis is influenced by the soaring prices, demand, and 
supply of certain types of meats.76 Producing meat from livestock is extremely 
inefficient.77 To produce one pound of beef, it requires more than “38 pounds of 
feed and 1,799 gallons of water.”78 Farm animals are fed enough grain to end 
                                                          
 67 Rick Morgan, Bill Gates and Richard Branson Are Betting Lab-Grown Meat Might 
Be the Food of the Future, CNBC (Mar. 23, 2018), https://www.cnbc.com/2018/03/23/bill-
gates-and-richard-branson-bet-on-lab-grown-meat-startup.html. 
 68 Id. 
 69 Emma Cosgrove, Memphis Meats Adds Tyson to Investor List with Cargill, Gates, 
Branson, Musk, More, AGFUNDER (Jan. 29, 2018), https://agfundernews.com/memphis-
meats-raises-17m-series-cargill-gates-branson-musk.html/. 
 70 Gene Marks, Lab-Grown Meat of the Future Is Here—and May Even Sustainably Fill 
Demand, GUARDIAN (Nov. 29, 2018), https://www.theguardian.com/business/2018/nov/29/ 
meat-poultry-sustainable-affordable-solution-lab-grown. 
 71 Morgan, supra note 67. 
 72 Jeff Bercovici, Why This Cardiologist Is Betting That His Lab-Grown Meat Startup 
Can Solve the Global Food Crisis, INC. (Oct. 24, 2017), https://www.inc.com/magazine/ 
201711/jeff-bercovici/memphis-meats-lab-grown-meat-startup.html. 
 73 Marks, supra note 70. 
 74 Id. 
 75 Isha Datar, Environmental Impacts of Cultured Meat, NEW HARVEST (Nov. 19, 2015), 
https://www.new-harvest.org/environmental_impacts_of_cultured_meat. 
 76 Karen McColl, Can We Feed the World?, 336 BMJ 1336, 1336–37 (2018). 
 77 Morgan, supra note 67. 
 78 Id.; Kai Olson-Sawyer, Meat’s Large Water Footprint: Why Raising Livestock and 
Poultry for Meat Is So Resource-Intensive, FOOD TANK (Dec. 2013), https://foodtank.com/ 
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world hunger twenty times over.79 
The total world population is forecasted to exceed nine billion people within 
thirty years;80 humanity simply cannot sustain meat production for a population 
of that size.81 In addition to food shortages, there will not be enough clean water 
to support a population of that size, let alone agricultural and horticultural 
needs.82 In light of the population, food, and water issues, proponents of cell-
culture meat are excited about the potential benefits because it is estimated that 
this technology requires ”100 times less land and 5.5 times less water” than 
traditional meat production.83 
Once the technology is better perfected and becomes more efficient, the time 
it takes to produce cell-based meats and to bring the product to table will be 
greatly reduced. Currently, it takes between eighteen to twenty-four months to 
bring a cow weighing over a thousand pounds to slaughter,84 and between eight 
to twelve weeks for a chicken weighing slightly over five pounds.85 For cell-
based meats, it is estimated that in ideal conditions this process can produce fifty 
thousand tons of pork in just two months.86 Again, production time of cell-based 
meats is likely to decrease, and yield is likely to increase once there are greater 
technological advances and streamlined processes in this area.87 
                                                          
news/2013/12/why-meat-eats-resources/. 
 79 Morgan, supra note 67; Mimi Bekhechi, Five Things Would Happen if Everyone 
Stopped Eating Meat, INDEP. (Jan. 31, 2016), https://www.independent.co.uk/voices/five-
things-would-happen-if-everyone-stopped-eating-meat-a6844811.html. 
 80 POPULATION DIV., UNITED NATIONS DEP’T OF ECON. & SOC. AFFAIRS, WORLD 
POPULATION PROSPECTS: THE 2017 REVISION 1 (2017), https://population.un.org/wpp/ 
Publications/Files/WPP2017_KeyFindings.pdf. 
 81 Morgan, supra note 67; Nathan Halverson, The World Already Would Be Out of 
Water if Everyone Ate Like Americans, REVEAL NEWS (Apr. 22, 2016), 
https://www.revealnews.org/blog/the-world-wouldve-already-run-out-of-water-if-everyone-
ate-like-americans/. 
 82 Halverson, supra note 81. 
 83 Morgan, supra note 67; Our Meatless Future: How The $1.8T Global Meat Market 




 84 Marybeth Feutz, Beef Cattle Life Stages, MY FEARLESS KITCHEN, 
https://www.myfearlesskitchen.com/beef-cattle-life-stages/ (last visited Apr. 16, 2020) 
(“[Cows fed with feedlot] are fed and taken care of until they reach around 1000–1200 
pounds, which is usually around 18 months old.… Because [grass fed cows] don’t receive 
the same amount of calories every day as their grain-fed counterparts, they are often closer 
to three years old before they reach their finished weight.”). 
 85 Danelle Wolford, How to Raise Meat Chickens: Part 1, WEED’EM & REAP, 
https://www.weedemandreap.com/raise-meat-chickens-part-1/ (last visited Apr. 16, 2020). 
 86 Damien Gayle, Artificial Meat Grown in a Lab Could Become a Reality This Year, 
DAILY MAIL (Jan. 17, 2012), https://www.dailymail.co.uk/sciencetech/article-2087837/Test-
tube-meat-reality-year-scientists-work-make-profitable.html. 
 87 LIZ SPECHT & CHRISTIE LAGALLY, GOOD FOOD INST., MAPPING EMERGING 
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Another rallying cry in support of cell-based meats is that they may reduce 
environmental impacts.88 As climate change worsens, reducing greenhouse gas 
emissions that contribute to the problem should be a priority for developed 
nations because their intellectual, financial, and technological resources put 
them in the best position to do so.89 The current estimate is that the world needs 
to cut about 40 percent of global greenhouse gas emissions by 2050 to avoid a 
global crisis.90 
Livestock is a significant contributor to greenhouse gas emissions.91 Farming 
livestock produces around 14.5 percent of global greenhouse gas emissions.92 
The gases produced include carbon dioxide, methane, and nitrous oxide, and the 
total production is around 7.1 gigatonnes of gases per year.93 Stem cells’ 
exponential multiplication means that the cells of only 150 cows could be needed 
to feed the entire world; food manufacturers currently require 1.5 billion cows 
to partially feed the world.94 However, cell-based meats will not solve the 
climate change problem entirely. Still, cell-based meats cutting into the livestock 
market can only help in the battle to reduce the effects of climate change, even 
if it is only by a reduction in a few percentage points of emissions.95 
Finally, animal rights activists are excited about this technology because it 
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ensures that no actual animals are caged in close, unsanitary conditions or 
abused in any manner.96 This should ease consumer concerns about animal 
husbandry, thereby opening a whole new market of meat products to those who 
did not previously eat meat due to abuse, raising conditions, or other ethical 
concerns.97 
However, opponents of this technology focus on how cell-based meats are 
simply theoretical; thus, any hopes that a product can tackle some of the biggest 
issues faced by modern humanity are purely conjectural.98 The cost of the meat 
and the cost of energy to grow the meat would cancel out any environmental or 
efficiency argument.99 In addition, cell-based meat arguments do not account for 
the fact that the rest of the cow is used to create other products.100 The 
byproducts made from the cow include leather, soaps, cosmetics, pet food, 
fertilizer, vaccines, and prescription medicines.101 
Even though other valid arguments related to uses of the animal carcass exist 
against the current state of cell-based meat technology, this technology will only 
continue to improve to increase the efficiency and lower the environmental 
impact of the process.102 In addition, if the cell-based meat technology takes off 
as its proponents claim, society can expect some market corrections to the 
leather industry where there will still be enough cows raised for these purposes 
and for meat, or other forms of synthetic leather created.103 Some companies are 
innovating to produce these other byproducts with just the cells from animals 
and without harvesting the animals.104 For example, Modern Meadow has 
developed a process to use genetically engineered yeast to produce bovine 
collagen.105 That collagen is then assembled into layers of leather that can be 
worked like traditional leather.106 
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A. Food Safety 
In addition to the environmental benefits, experts also believe that cell-based 
meats could be safer than traditional meats.107 Salmonella and Escherichia 
coli are always a concern when preparing traditional meats for consumption 
because these bacteria exist in nearly all livestock meats and can be transferred 
to humans if the meat is not cooked properly.108 When people ingest Salmonella 
or E. coli, they can experience a wide range of symptoms from mild discomfort 
to severe dehydration.109 This is also known as food poisoning.110 
Not all strains of these bacteria cause illness.111 The human body has strains 
of E. coli within its normal biome.112 Similarly, cattle and poultry also have 
certain strains of these bacteria in their respective systems that are not 
pathogenic to them.113 However, the E. coli found in their gastrointestinal track 
is pathogenic to humans.114 These specific strains of E. coli can contaminate 
food, like ground beef, during the food processing stage.115 
It takes a few days for the bacteria to promulgate enough to cause harm to the 
human body.116 This is when it is called food poisoning.117 If enough people get 
sick, then the manufacturer may recall the product, which is a costly process.118 
The USDA published figures showing that, in 2018, there were 31 beef recalls 
amounting to 13,185,563 pounds of product lost and 34 poultry recalls 
amounting to 1,214,839 pounds of product lost.119 
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The introduction of pathogens into food will not be a problem for cell-based 
meat products.120 Since cell-based meats are grown in sterile conditions, 
scientists can test for and prevent contamination before the product goes to 
market.121 The introduction of cell-based meats to market may reduce the 
incidents of commercial pathogen or other emerging diseases, which are linked 
to livestock farming.122 The ability to control exactly what is in the food product 
throughout all stages of growth will save costs by avoiding the expensive recalls 
and preventing illness.123 
In addition, cell-based meats could help reduce the growing concern of 
superbugs that has resulted from widespread antibiotics use in livestock.124 
When an antibiotic is overused without killing off all the intended bacteria, the 
remaining bacteria develop genes that make the bacteria resistant to further drug 
treatments.125 Bacteria also possess the ability to give these drug resistant genes 
to neighboring bacteria.126 Thus, the drug resistance spreads to all the surviving 
bacteria.127 Resistant bacteria are found in livestock, meat, and people 
worldwide.128 Farmers or doctors must find different or new antibiotics to 
effectively treat illnesses caused by these drug-resistant bacteria.129 Bacteria that 
are resistant to two or more antibiotics are called superbugs.130 
Superbugs are a serious concern for the public health and medical community. 
About two million people get sick from superbugs annually and, of those, about 
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twenty-three thousand die from the pathogens.131 Therefore, coming up with 
new treatments and new ways to keep bacteria out of the food chain is very 
important. 
As with normal pathogens, cell-based meats are not susceptible to superbugs 
infiltrating the product.132 For example, Memphis Meats claims that neither 
antibiotics nor growth hormones are required in its process because of the sterile 
lab conditions.133 Therefore, there is no risk of antibiotic resistance being created 
in cell-based meats because there is no introduction of antibiotics into the 
product.134 In addition, sterile laboratory conditions eliminate the risk of any 
superbug being in the food product itself.135 Thus, the growth of cell-based meats 
would stop the cycle of creating food-based pathogens and eliminate the 
introduction of superbugs into food.136 
The sterile conditions in which the cell-based meats are grown, cultivated, 
and processed reduce the risk of food-based pathogens.137 Not only do they 
reduce the risk of these pathogens, but they also reduce the creation of bacteria 
that are resistant to multiple antibiotics.138 The increased level of food safety 
will put consumers at ease and save manufacturers money that would have gone 
to the recall of their respective products.139 
B. Novel Foods 
Meats grown in a lab have the potential to be healthier than those that are 
traditionally harvested.140 The manufacturers can alter the cell culture or a cell’s 
genomic makeup so that cell-based meats would be fortified with beneficial 
vitamins and fatty acids.141 For example, omega-3s found in fatty cold-water fish 
could be produced by cow cells which would increase the nutritional value of 
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the cow product.142 Even unhealthy saturated fats could be eliminated and 
replaced with more healthy polyunsaturated fats.143 The combinations are 
limitless. Theoretically, different genomes from different species’ cells could be 
“combined to produce meat blends with new flavor, texture, and nutritional 
profiles.”144 
Researchers such as Liz Specht, a senior scientist at the Good Food Institute, 
are confident that they can alter conditions so that they can produce healthier 
meats, stating, “Clean meat version 1.0 involves recapitulating as quickly as 
possible the products that consumers already know and love, but for version 2.0, 
the question is, could we actually tailor the composition of these cells to make 
them, for example, healthier?”145 Ms. Specht notes that it is possible to simply 
infuse fatty acids by adding the compounds to the culture growth medium.146 
Other nutrients may be effectively infused into the cell-based meat cells in a 
similar fashion.147 Another way to add nutrients and fats to the cell-based meats 
would be to genetically modify the cells so that they produce the specific 
compound desired.148 
III. THE STATE RESPONSE TO CELL-BASED MEATS 
The response to cell-based meats has already begun on the state level. State 
lawmakers have started to propose legislative action against cell-based meats in 
order to protect their farmers. Bills have either been proposed or passed in 
Montana,149 Kentucky,150 North Dakota,151 and Missouri.152 At least thirteen 
state bills proposed in 2019 have to do with labeling requirements for cell-based 
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meat products.153 In 2019, fourteen states total passed seventeen laws against 
cell-based meat labels.154 
House Bill 311 in Kentucky, which was proposed in late February 2019 and 
signed into law on March 21, 2019, amended the state’s food labeling laws.155 
A food product is now considered misbranded if “it purports to be or is 
represented as meat or a meat product and it contains any cultured animal tissue 
produced from in vitro animal cell cultures outside of the organism from which 
it is derived.”156 This means that all cell-based meats would need to be explicitly 
labeled as such on the packaging or the relevant company would face penalties 
from the state for misbranding a food product.157 This is a preemptive strike 
against cell-based meat companies and technology in order to protect Kentucky 
farmers and “real” meats.158 
Washington State has proposed a bill, the Natural Meat Protection Act, that 
would criminalize the sale of cell-based meats and restrict funding for the 
research of new technologies.159 The bill states that “(1) [a] person may not 
advertise, sell, or offer for sale a cell-cultured meat product in the state of 
Washington [and] (2) State funding may not be appropriated or expended to fund 
research or development of cell-cultured meat product.”160 Lawmakers in 
Washington have stated that they are concerned about the safety of the lab grown 
product because the food product is untested.161 As of January 2020, the bill has 
not made it out of the Washington House of Representatives.162 
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Many farm trade organizations have been vocal against this new 
technology.163 For example, Kentucky Agriculture Commissioner Ryan Quarles 
commented on the Kentucky bill saying, “In a couple of years, lab-grown meat 
will be available across America. . . . It’s important that we stand up and protect 
our cattle farmers, and it’s important that consumers know the difference 
between a steak that comes from a farm and a steak grown in a lab.”164 This 
sentiment is generally shared by farm lobbyists. 
Some of these bills are being challenged in court by the American Civil 
Liberties Union (“ACLU”) and other faux meat groups like Tofurky, which 
produces a tofu turkey substitute that might fall within the new labeling 
requirements for cell-based meats.165 The challengers state that a new Missouri 
law will only confuse the average consumer and discriminate against out-of-
state retailers.166 In addition, the challenge claims that “the law plays favorites 
to benefit the meat industry, violates free-speech, … violates a law preventing 
discrimination against out-of-state companies,” and is too vague to follow.167 
Pro cell-based meat groups have responded to the states’ concerns by rallying 
lobbyists and even sending a letter to President Trump in hopes of clarifying the 
regulatory and legal issues surrounding the new technology.168 Sarah Sorscher, 
the regulatory affairs representative for the Center for Science in the Public 
Interest, challenges the idea that consumers will be confused by the labeling 
laws.169 Ms. Sorscher said, “We think the issue of whether they use a term like 
meat is a proxy for this bigger issue, which is that the meat industry is concerned 
about competition from these products. . . . The bills don’t seem to be directed 
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at solving a problem in the marketplace. It is about fighting off competition.”170 
Data showing that farming is becoming less viable supports Ms. Sorscher’s 
position.171 
IV. THE LAW: PATENT LAW, REGULATORY LAW, AND THE HATCH-
WAXMAN ACT 
A. Patent Law in General 
Intellectual property rights are granted to any original creation of the mind in 
the fields of art, literature, or science to protect the work for a predetermined 
period of time.172 IP rights are given to creators or inventors in the form of 
copyrights, patents, trademarks, or trade secrets.173 These forms of protection 
trace their roots back to England and are well ingrained in our society.174 IP 
rights are essential in allowing the creator or manufacturer of a work to protect 
his or her energy, time, and monetary investments that were poured into its 
creation or process without the fear of a competitor using the creator’s 
investments to undercut them in the marketplace.175 
All patents must be novel, useful, and non-obvious.176 “Novel” means that the 
invention has not been described in a published patent application or other 
publication, nor in the market, before the submitted patent application.177 When 
a patent is challenged, the claim of a novel patent can extend up to one year prior 
to the submission of the patent application.178 
When evaluating the term “useful,” the invention to be patented needs to have 
a purpose.179 There are very few patent applications that have been denied 
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because the invention was not useful.180 Almost anything that someone seeks a 
patent for does something that can be determined to be useful.181 
Finally, the “not obvious” term means that the invention must be different or 
not obviously the same as what has come before the thing seeking to be 
patented.182 The standard of judgment is from the perspective of “an ordinary 
person skilled in the applicable field.”183 In other words, the invention is obvious 
if a person, who knows the ins and outs of a certain field, “would have known 
to combine previously-existing inventions to result in your invention, without 
having seen your patent application first.”184 
The cell-based meat manufacturers will obtain patents on a number of 
processes and cell lines.185 With the average patent application timeline lasting 
twenty-one months,186 the manufacturers will have to plan for what they seek 
patents on and how they will patent their ideas.187 When seeking patents, there 
are two types of patents that these meat manufacturers can obtain: utility patents 
and design patents.188 
Utility patents cover machines, manufactured articles, processes, chemicals, 
cells lines, or any combination of these.189 Utility patents last for at least twenty 
years from the initial filing or earliest priority date in a patent application to the 
United States Patent and Trademark Office (“USPTO”).190 However, 
maintaining these types of patents is not free.191 Maintenance fees are paid 
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throughout the life of a utility patent.192 If the fees are not paid, the patent will 
expire earlier than the twenty-year term.193 
Design patents are granted to the holder when the aesthetic configuration of 
the patented object is novel, useful, and not obvious.194 A design patent does not 
cover the function or construction of the invention like its utility patent 
counterpart.195 As of 2015, they are valid for a period of fifteen years from the 
date of issue.196 Unlike utility patents, there are no maintenance fees required to 
maintain the validity of design patents.197 
After a patent expires, the invention is freely available to all.198 Therefore, it 
is incredibly important for the holder to use the duration of the patent as 
efficiently as they can or they risk losing potential profits from being the sole 
provider of the product or licensing the subject of the patent to others.199 
A manufacturer or inventor cannot seek a patent on the following: processes 
that are purely mental;200 mathematical algorithms or formulas that do not have 
a real-world effect, although, “a formula or algorithm may be claimed as part of 
a method”;201 arrangements of printed words;202 naturally occurring things that 
have not been changed;203 and the underlying principle to a device or method 
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which, based on new scientific principles, cannot be patented.204 Manufacturers 
of cell-based meats will have to walk a fine line in order to prove that cell-based 
meats do not merely involve a formula or a naturally occurring thing, but rather 
involve an object or process that can be patented so that they can keep their 
products protected.205 
The patents sought for cell-based meat products could be both utility and 
design patents.206 The utility patents will be for the manufacturing processes of 
the cell-based meats, the machines used in the process, the cell lines, and the 
chemicals used throughout the process.207 Even though there is not much use for 
design patents in this field, there will be applications tied to how the finished 
meat products look.208 Eventually, the manufacturers will want to design the 
meat to look like T-bone steaks or real chicken breast;209 therefore, the 
manufacturers will want to have patents on those specific designs.210 
It is generally understood that the stronger the protections available, the better 
these creations of the mind can be protected.211 Specifically, strong patent laws 
for biotechnology creations create more incentives for research and more 
opportunities for securing funding, which can lead to earlier discoveries.212 In 
addition, stronger biotechnology patent laws create greater public awareness of 
the invention because patents are disclosed to the public; this further drives the 
funding and incentives to create new technologies.213 
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However, strong patent laws are not without a number of disadvantages as 
well.214 For example, biomedical research and methods may be restricted 
broadly by creating a fee that researchers must first pay.215 Another disadvantage 
is that the patent incentives are wiped out if the market is not profitable.216 A 
disadvantage that is also noticeable is the cost of health care may be driven up 
if patent holders charge excessive prices for the use of their respective 
inventions.217 
A strong patent system will drive a certain industry to create more and will 
boost the economy of that industry.218 However, this may cause a product to 
become unobtainable by the low-income population.219 A weaker protection 
system allows for many players to compete in the same industry, which makes 
a product more widely available and affordable.220 Thus, regulators must walk a 
fine line in order to promote the economy of an industry, while also ensuring 
products are not out of reach for some of the population due to high prices.221 
A recent example of how strong patent laws can cause problems in biomedical 
research occurred with the BRCA2 gene.222 The BRCA2 gene is a well-known 
gene that, when mutated, will eventually cause breast cancer.223 Even though it 
was very sought after, only one company, Myriad Genetics, held the rights to 
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the gene due to extremely strong IP protections.224 Anyone who wanted to 
research breast cancer and the BRCA2 gene had to either obtain permission from 
this company or use their services.225 This led to scarcely any research being 
done on breast cancer, outside of Myriad Genetics, because the company was 
charging an obscene amount to allow others to use the gene in their research.226 
This monopoly alone hindered an entire area of cancer research across the 
nation.227 
Eventually, a lawsuit was brought against Myriad Genetics by the Association 
of Molecular Pathology.228 The suit by the Association of Molecular Pathology 
alleged that Myriad Genetics’ patents were invalid.229 Specifically, the 
association alleged that the naturally occurring products of nature, such as 
specific isolated genes, were unpatentable and that the diagnostic and screening 
tests were just basic procedures of science that did not yield any real-world 
transformations.230 United States law defines patent eligible to include “any new 
and useful process, machine, manufacture, or composition of matter, or any new 
and useful improvement thereof.”231 However, if the property falls under an 
excluded category, such as a “naturally occurring article,” as defined in case law, 
then it is not patent eligible.232 
Association for Molecular Pathology v. United States Patent and Trademark 
Office233 led to important cases, such as Genetic Technicians v. Bristol-Myers 
Squibb Co., which defined intellectual property rights for genes and other 
biotechnologies.234 In Association for Molecular Pathology, the court held that 
any naturally occurring gene may not be eligible for patent rights;235 however, 
if the gene were to be modified in some way from how it occurs naturally, then 
there may be IP rights given to the creator.236 Therefore, if a gene matches 
molecule for molecule what one could find naturally occurring in the wild, then 
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one cannot stake a claim to it.237 The scientists had to actually change something 
in the DNA code in order to establish a patent claim.238 
The rule related to gene patenting has been transferred not just to sequences 
of DNA, but also to patenting entire cell lines.239 Essentially, one may patent a 
cell line if he or she can show that it satisfies the initial definition of a patent—
novel, useful, and non-obvious—and that the cell line was created artificially.240 
Currently, there are over two thousand patented cell lines.241 In Sherley v. 
Sebelius, two scientists questioned various stem cell lines after President Obama 
expanded the ability of researchers to use different lines of stem cells.242 
More often, the courts will see suits over the patented process of creating and 
maintaining a cell line. For example, the United States Court of Appeals for the 
Federal Circuit in Pharmastem Therapeutics, Inc. v. Viacell, Inc.243 oversaw a 
challenge to a patented method of extracting stem cells from the umbilical cord, 
cryogenically freezing those cells, and then later thawing those stem cells for 
use.244 These living cells can be difficult to work with and keep alive, so finding 
techniques to preserve, feed, and keep the cells viable for experimentation 
becomes more important than protecting the cell line itself.245 If the cells cannot 
be kept alive, what is the point in patenting the line in the first place? A large 
focus of all scientists, whether in a specific industry or at a university, is on the 
process of how to work with their cell lines.246 
This concept is extremely important for cell-based meat because the stem 
cells that will eventually become the meat or fat will need to be kept alive and 
viable to become the product.247 Also, the same stem cells may be edited for 
faster growth or to produce vitamins, and the scientists will want to protect their 
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specific lines of cell-based meat.248 Overall, the scientists will want to protect 
the specific processes by which they create products.249 
In addition, the cell-based meat lines, when naturally in their host animal, 
have all the nutrients and support systems of that animal to thrive.250 These 
consist of things such as vitamins and nutrients, a constant flow of oxygen, and 
a medium to grow in.251 Therefore, the scientists will have to replicate this 
environment to keep the cells happy and thriving.252 This will also take specific 
processes that they will want to patent and protect.253 
B. Regulatory Oversight 
There has been much dispute as to which regulatory agency will oversee cell-
based meat production.254 As of late October 2018, the FDA and the USDA have 
decided to share this responsibility.255 The FDA will have regulatory oversight 
over good manufacturing practices, the quality of the food, labeling, and every 
other major food regulation that would apply under the Food, Drug, and 
Cosmetic Act (“FDCA”).256 Under this agreement, the USDA will have 
regulatory authority over harvesting and marketing.257 
The FDA will have regulatory oversight over the food product of cell-based 
meats.258 This authority comes from 21 U.S.C. § 321 within the FDCA.259 Under 
FDA law, there is no debate over whether cell-based meat is considered food.260 
The term “food” means: “any articles used for food or drink for man or other 
animals, chewing gum, and articles used for components of any such article.”261 
Even as circular as this definition is, there is no doubt that cell-based meats are 
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to be used for food.262 
A company looking to get their cell-based meat approved for consumption 
will have to address any additives it puts in its product.263 The term “food 
additive” under the FDCA means: 
Any substance, the intended use of which results or may reasonably 
be expected to result, directly or indirectly, in its becoming a 
component or otherwise affecting the characteristics of any food 
(including any substance intended for use in producing, 
manufacturing, packing, processing, preparing, treating, packaging, 
transporting, or holding food; and including any source of radiation 
intended for any such use).264 
An additive in this process could be the recombinant DNA, the growth 
medium of the cells, or the other nutrients the cells need to become meat 
proteins.265 Each of these could easily be understood as a substance which 
becomes a component of the food.266 For example, the company may want to 
manufacture cell-based beef that has extra vitamin A, C, and D to provide for a 
better-balanced diet.267 The company can do this either by adding extra vitamins 
to the growth medium or by adding recombinant DNA to the cells so that the 
cells produce the vitamins themselves.268 In order to use this process, the 
manufacturers will need to get approval from the FDA under the food additive 
provisions because both of the additives become a component of the food.269 
Another approval that companies may need from the FDA is processed food 
approval.270 The term “processed food” means: “any food other than a raw 
agricultural commodity and [this] includes any raw agricultural commodity that 
has been subject to processing, such as canning, cooking, freezing, dehydration, 
or milling.”271 This is not an exhaustive list and what is considered “processed” 
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is up for interpretation by the FDA.272 Here, there could be a debate over whether 
or not cell-based meats are considered “raw agricultural commodities.”273 A raw 
agricultural commodity is defined as, “any food in its raw or natural state, 
including all fruits that are washed, colored, or otherwise treated in their 
unpeeled natural form prior to marketing.”274 They may be considered raw 
agricultural commodities because the manufacturers grow the raw cells up from 
the primary material, much like plants are grown from seeds.275 However, 
because these meats are going through many different processes like packaging, 
freezing, and antibacterial or antifungal treatments, it would be easy for the FDA 
to find that these are “processed foods.”276 Under the FDCA, a processed food 
is any food that is processed for consumption.277 
C. Hatch-Waxman Primer 
The FDA is unique as a regulatory agency because it has the legal framework 
available to handle any safety and IP challenges to cell-based meat.278 When it 
comes to patent rights, the FDA has a special statute called the Hatch-Waxman 
Act, codified at 21 U.S.C. § 355; it modified the FDCA and was formally known 
as the Drug Price Competition and Patent Term Restoration Act.279 Hatch-
Waxman was a bipartisan effort undertaken by a Republican Senator from Utah 
and a Democratic Representative from California.280 The act was enacted with a 
few goals in mind; specifically, as the FDA stated, “[The] main goal . . . in this 
area is to promote innovation, while also promoting rapid access to low-cost, 
safe and effective generic drugs.”281 It represents a bargain between the pioneer 
drug and the generic drug industries.282 
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Moreover, Congress wanted to help companies get their generic drugs to 
market faster and to overrule Roche Products, Inc. v. Bolar.283 In Roche 
Products, Inc., the United States Court of Appeals for the Federal Circuit held 
that even testing a generic drug to prepare it for FDA approval while the brand 
drug’s patent was still in effect was patent infringement under 35 U.S.C. § 
271.284 This meant that companies that wanted to create a generic drug had to 
wait until the corresponding brand drug’s patent had expired before they could 
start trials or testing for purposes of the FDA’s New Drug Approval (“NDA”) 
process.285 
Prior to the enactment of Hatch-Waxman, FDA officials developed a policy 
for the approval of abbreviated NDAs in 1962.286 The policy change required 
that, before introduction into interstate commerce, evidence that all new drugs 
be “safe and effective for their intended use and recognized by the FDA as 
such.”287 The “safe and effective” requirement must be proven by an “adequate 
and well-controlled” clinical study.288 This FDA approval with the safe and 
effective designation constituted part of the NDA process.289 
Generic drug approval depends on when the FDA approves the brand drug’s 
NDA.290 A generic drug applicant could apply for approval with a “paper 
NDA.”291 An NDA applicant using a paper NDA relies upon data from 
“published scientific literature” to demonstrate effectiveness of the generic 
product, as well as the brand drug approved application.292 However, testing can 
take years to complete, and an exuberant amount of money must be spent to get 
FDA approval of these NDAs.293 In the past, this caused extensive delays in 
getting to market, which cost manufacturers money.294 Generic drug 
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manufacturers were dissatisfied with their disadvantage in the marketplace.295 
If generic manufacturers did not want to pursue a paper NDA, then these 
manufacturers had to submit a full NDA.296 Therefore, many brand drugs would 
go without a generic counterpart because of the risks of patent infringement, 
financial loss, and generic drug manufacturers being outcompeted by other 
generic drug manufacturers.297 These risks and this fear of generic drug 
manufacturers created an artificial extension to the exclusivity period for the 
brand name drug manufacturers that was taken advantage of but was not 
intended by IP laws.298 
Pioneer manufacturers, meanwhile, were frustrated that the patent life of a 
product was consumed by a lengthy regulatory process.299 The pioneer 
manufacturers could not legally market their respective drugs without FDA 
approval, which increased the overall market frustration.300 Both the pioneer 
brand manufacturers and the generic drug manufacturers turned to Congress for 
help.301 
Under the 1984 Hatch-Waxman Act,302 the FDA may approve a generic drug 
version’s abbreviated NDA (“ANDA”) after: “(1) all relevant product and use 
patents have expired for the pioneer drug and (2) all relevant periods of market 
exclusivity for the pioneer drug have also expired.”303 If these conditions are 
met, then a generic drug may be submitted for approval if the generic version is 
the same as the pioneer drug in all material respects.304 In these cases, all a 
generic manufacturer must do to receive the FDA’s approval is submit the 
ANDA, no “further consideration about the safety and effectiveness of the 
generic [drug]” is required.305 This is because if the generic drug is the same as 
the pioneer drug which already showed safety and efficacy through the NDA, 
then there is no need to demonstrate safety and effectiveness again.306 
If, however, the generic drug does differ from its pioneer counterpart (such as 
by having a different active ingredient, dosage strength, or form), then the 
                                                          
 295 The Hatch-Waxman Act: A Primer, supra note 286; 21 U.S.C. § 355. 
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visited Apr. 20, 2020). 
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generic drug applicant must submit a “suitability petition” to the FDA.307 The 
petition needs to demonstrate that the difference between the drug and the 
pioneer drug is not enough to preclude ANDA approval and that no additional 
studies are needed to show safety and efficacy.308 This compromise allows a 
generic drug company to use the innovator’s data in its submission, substantially 
cutting costs to generic drug manufacturers.309 
In return for allowing generic manufacturers to use the pioneer drug data to 
support the ANDAs, the pioneer manufacturers receive patent-term extensions 
and market exclusivity.310 The terms of a patent may be extended to compensate 
a patent owner when a FDA-regulated review has caused a delay in using that 
patent in the marketplace after it has been issued.311 The length of the extension 
depends on how long the regulatory review periods last.312 For example, the 
regulatory review periods for a new drug include the testing phase and the 
agency approval phase.313 A drug manufacturer will submit the required 
Investigational New Drug (“IND”) application before pre-clinical testing is 
performed to determine if the drug is reasonably safe for humans;314 the period 
between when the IND and the NDA are filed is the testing phase.315 
The period between filing the NDA and the FDA’s approval is considered the 
approval phase.316 The testing phase of a drug approval can last up to nine 
years,317 and the average approval phase normally lasts less than two 
years.318 The patent term extension is calculated by first reducing the extension 
by any time that the applicant did not act with due diligence during the approval 
phase, which is based on a finding by the FDA.319 After the calculated time, if 
any, has been subtracted for a lack of due diligence, “one-half of the time 
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remaining in the testing phase would be added to the time remaining in the 
approval phase”320 and that time is given as an extension to the patent.321 
V. CAUTIONS FOR USING THE HATCH-WAXMAN ACT AS A MODEL 
The Hatch-Waxman Act has solved several issues when it comes to providing 
more generic drugs as a low-cost alternative to the average consumer.322 
However, the Hatch-Waxman Act contains a few loop-holes and workarounds 
that brand companies can abuse to make profits and delay the introduction of the 
generic version of a drug.323 Brand drug companies will engage in actions such 
as reverse payments, citizen petitions, and product hopping in order to find loop-
holes or circumvent the Hatch-Waxman Act.324 By recognizing the ways in 
which these companies have taken advantage of this act, Congress and 
regulatory agencies can incorporate better language into legislation and 
formulate rules that prevent brand cell-based meat companies from delaying 
competitors from entering the market and holding a monopoly.325 
A. Reverse Payments 
The first and most common way brand companies circumvent the Hatch-
Waxman Act is through reverse settlement payments or simply reverse 
payments.326 Reverse payments are used to pay off generic drug filers seeking 
to enter a specific drug space.327 Once generic drugs enter the market, they 
quickly take up a large portion of the market, cutting into brand companies’ 
profits.328 To continue making profits on their drugs, brand companies will pay 
                                                          
 320 See id. § 156(c)(2); Small Business Assistance: Frequently Asked Questions on the 
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 325 See id. at 614. 
 326 Id. at 596–97; Steven Adamson, Pharmaceutical Patent Wars, Reverse-Payment 
Settlements, and Their Anticompetitive Effects for Consumers, 30 LOY. CONSUMER L. REV. 
241, 252 (2018). 
 327 Meagher, supra note 323, at 589, 596–97. 
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generic filers to delay entering the market.329 The brand companies can legally 
do this by suing the generic manufacturers for patent infringement, regardless of 
the validity of the suits, and then settling quickly with the generic 
manufacturers.330 In fact, reverse payment settlements actually “cost American 
consumers anywhere between $0.6 billion and $7.5 billion each year, or $3.5 
billion each year on average.”331 
The concern for the future cell-based meat market will be that major brand 
producers will want to engage in a similar practice.332 Not only would this be 
bad for consumers, but this would be bad for free-market principles that guide 
the economy.333 By preventing competitors from entering into the market 
through reverse settlement payments, a cheaper, “generic” alternative will be 
kept from the common consumer.334 
Allowing reverse payments would also create a pseudo-monopoly.335 A 
monopoly over this budding industry would stifle ingenuity and growth. In an 
industry that needs more innovation to become viable, this could be a death 
sentence.336 
Therefore, Congress, the FDA, and the USDA need to ensure they include 
language that would prevent reverse payments.337 Whether this is through an 
organic act that would give the FDA and USDA supervisory power, or by 
granting antitrust agencies such as the FTC the power to review the settlements, 
federal authorities need to learn from how companies have circumvented Hatch-
                                                          
 329 Id. at 597. 
 330 Id.; see Ramsi A. Woodcock, Uncertainty and Reverse Payments, 84 TENN. L. REV. 
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70033.html; see generally Hospitals & Monopoly, OPEN MKTS., 
https://openmarketsinstitute.org/explainer/hospitals-and-monopolies/ (last visited Apr. 20, 
2020) (explaining the impact of monopolies in the medical provision). 
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Waxman to prevent the same kind of actions.338 Reverse settlements would be 
greatly detrimental to the industry and to consumers. 
B. Citizen Petitions 
A second way brand companies circumvent the Hatch-Waxman Act is 
through citizen petitions.339 Congress has allowed any citizen to petition an 
agency;340 citizens may petition agencies to take or refrain from taking certain 
administrative actions.341 Pursuant to the Administrative Procedure Act 
(“APA”),342 the FDA must give the public a right to petition an agency action.343 
Citizen petitions were intended to open a line of communication between the 
public and the agency so that all important information concerning the agency 
action is presented to the agency.344 
Brand companies have been able to use these citizen petitions as a tactic to 
delay agency actions, such as delaying the approval of competing generic 
drugs.345 Some savvy companies will file a 505(q) citizen petition with the 
FDA.346 These citizen petitions are mostly used to delay generic drug entry.347 
When a citizen petition is filed, the FDA must respond within one hundred and 
fifty days after the filing date.348 A brand company will typically file a petition 
a few weeks before a final decision on a generic ANDA, forcing the FDA to 
respond to the petition before it completes the generic drug’s approval.349 This 
is an effective tactic for pushing back the approval of the generic drug’s 
ANDA.350 
This tactic involves what is known as an “ ‘eleventh hour’ petition because 
companies would file them ‘on the eve of drug approval for the purpose of 
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 339 Meagher, supra note 323, at 600. 
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delay.’ “351 Citizen petitions are long and complex.352 Thus, the generic drug’s 
approval is often delayed for the full one hundred and fifty days.353 This tactic 
effectively delays the approval of generic drugs and circumvents the amended 
application process which Hatch-Waxman was designed to accelerate.354 
The concern for legislation protecting cell-based meat intellectual property 
and encouraging competitors to enter the market is that brand companies will 
use citizen petitions to delay the approval of any other “generic” version of cell-
based meat.355 Being delayed up to half a year has a major effect on profits that 
generic companies could earn and profits that brand companies could retain.356 
Any legislation would need to prevent or limit this stalling tactic in order to 
encourage fair market competition, to protect intellectual property rights, and to 
aid the consumer.357 
C. Product Hopping 
The final way a company may circumvent the Hatch-Waxman Act is through 
“product hopping.”358 Product hopping is a strategy used when a brand 
company’s patent exclusivity is about to expire, allowing for generics to seek an 
ANDA to enter the market.359 
The brand company will pull the brand drug from the market and quickly 
                                                          
 351 Meagher, supra note 323, at 600–01. 
 352 Id. at 601. 
 353 Id. at 600. 
 354 Id. 
 355 Elaine Watson, Future Meat Technologies Raises $14m to Commercialize Cell 
Cultured Meat: ‘We See a Path to Reality Here, It’s Not Just Something on a Power Point 
Presentation,’ Says S2G Ventures, FOODNAVIGATOR-USA (Oct. 11, 2019), 
https://www.foodnavigator-usa.com/Article/2019/10/11/Future-Meat-Technologies-raises-
14m-to-commercialize-cell-cultured-meat. 
 356 Sarah Zhang, How Pharma Companies Use ‘Citizen Petitions’ to Keep Drug Prices 
High, THE ATLANTIC (Mar. 8, 2017), https://www.theatlantic.com/health/archive/2017/03/ 
pharma-citizen-petitions-drug-prices/518544/. 
 357 Ben Hargreaves, US FDA to Crackdown on Citizen Petition ‘Loophole’ Hindering 
Generic Entry, OUTSOURCING-PHARMA.COM (Oct. 4, 2018), https://www.outsourcing-
pharma.com/Article/2018/10/04/US-FDA-to-crackdown-on-citizen-petition-loophole-
hindering-generic-entry (explaining that the FDA is working on informal rulemaking to 
slow down or stop the abuse of citizen petitions). 
 358 New York ex rel. Schneiderman v. Actavis PLC, 787 F.3d 638, 638, 643 (2d Cir. 
2015); see generally Phebe Hong, Stopping the Pharmaceutical “Product Hopping”, BILL 
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substitute the drug for the company’s own generic version.360 This forces 
consumers to use the company’s generic drug instead, which allows the brand 
company to continue its monopoly over a specific part of market.361 
Product hopping was addressed in the case of New York v. Actavis.362 In 
Actavis,363 an antitrust action was commenced against Actavis.364 Namenda IR 
was the Defendant’s drug designed to treat Alzheimer’s disease, but it was close 
to the end of its patent exclusivity period.365 Actavis introduced a new version 
of the drug called Namenda XR.366 The new version of the drug still had 
exclusivity through patents.367 This would restrict other companies from 
introducing other generic versions of the same drug to the market for many 
years.368 To avoid competition, Actavis “decided to withdraw virtually all 
Namenda IR from the market in order to force Alzheimer’s patients who depend 
on Namenda IR to switch to XR before generic IR becomes available.”369 This 
product hopping by Actavis restricted any generic competition on its drug, and 
the cost of having the patients switch drugs “further ensure[d] that Defendants 
would maintain their effective monopoly in the relevant drug market beyond the 
time granted by their IR patents” and the Hatch-Waxman Act.370 
The Court of Appeals for the Second Circuit held that “a scheme to coerce 
patients to switch from an old product to a new one, by withdrawing from the 
market with an intent to affect generic competition, violated antitrust laws.”371 
Even though antitrust laws have made this tactic effectively illegal, the Hatch-
Waxman Act does not prevent this tactic,372 and because it is not prevented by 
Hatch-Waxman itself, the FDA will not catch drug companies using product 
hopping.373 Companies can therefore product hop for years before they are sued 
and challenged in court.374 As a result, brand companies will reap more rewards 
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in profits and recognition than they will pay out in fines levied for antitrust 
violations.375 
Congress will have to include anti-product hopping language in any 
legislation it enacts.376 If cell-based meat brand companies could pull their 
products and introduce modified versions in order to keep exclusivity on their 
products, cell lines, or growth processes, major companies could secure 
monopolies over their respective areas of the market.377 If these monopolies 
were to fly under the radar of federal regulators, this would keep prices higher 
for consumers and inhibit critical innovation.378 
The Hatch-Waxman Act has made great headway in encouraging competition 
in the drug markets and cutting costs to consumers.379 Furthermore, lessons 
learned about how companies have worked around the act can be used by 
Congress and regulatory agencies when enacting new legislation or 
promulgating new rules.380 If federal authorities want to protect secondary, 
“generic” cell-based meat companies looking to compete in the budding market, 
then rules and laws should be implemented to inhibit reverse payments, citizen 
petitions, and product hopping. By preventing these tactics, monopolies can be 
prevented, costs can be cut, and innovation can be encouraged.381 
VI. ANALYSIS OF POTENTIAL PATENT PROBLEMS RELATED TO 
CELL-BASED MEATS 
Legislation such as the Hatch-Waxman Act solved many issues for both brand 
and generic drug manufacturers by creating an extended period for companies 
to maintain their patents on drugs while these drugs went through an FDA 
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approval process.382 With the framework of Hatch-Waxman in mind, Congress 
could create a new amendment to the FDCA that would give a time extension to 
cell-based meats patents.383 
As stated above, there will be many regulatory approval stages that cell-based 
meat manufacturers will have to go through before they can introduce their 
products into interstate commerce.384 The FDA will oversee areas such as lab 
safety (including clean working areas and good manufacturing processes),385 cell 
collection from animals, maintaining a clean and unadulterated cell-bank,386 and 
ensuring a clean cell-growth and differentiation process for public safety.387 
Even though the FDA has the infrastructure in place and the knowledge base 
to handle these inspections and approvals,388 this new technology will not come 
without some hiccups. FDA inspectors will need to familiarize themselves with 
the terminology of the various scientific moving parts, the inspection schemes 
will need to be optimized for the most efficient flow of a visit, and the scientists 
who have never before been inspected by the FDA, let alone a federal 
government agency, will need to adapt and change the way in which the 
company stores and communicates information about its growth process.389 All 
of these moving parts will create delays and increase the time it takes for lab-
grown meat manufacturers to get their products to grocery store shelves.390 
In addition to FDA approval of the processes and quality of lab-grown meats, 
manufacturers will also need approval from the Food Safety and Inspection 
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Service (“FSIS”), an agency of the USDA.391 After the FDA’s inspection and 
approval, there will be a transition from the FDA to the USDA for oversight at 
the cell harvest stage.392 The USDA will then oversee the production and 
labeling of the lab-grown meats.393 Although the USDA has the appropriate 
infrastructure for handling labeling and food production oversight, this 
infrastructure is currently organized and designed around living animals.394 The 
USDA is not experienced in working in a pure laboratory setting.395 This will 
provide a few extra hurdles to overcome when deciding what is going to be on 
a label and how the harvesting of the product will occur.396 This will initially 
cause delays as there will inevitably be some trial and error to optimize the 
system for reporting and the collection of information.397 
This transition of regulatory oversight is also something that the government 
and the FDA have experience in through coordinated frameworks.398 There are 
many areas in which different government agencies share responsibilities.399 For 
example, the Federal Insecticide, Fungicide, and Rodenticide Act has led to an 
understanding that the FDA and EPA will jointly regulate antimicrobial agents 
depending upon the use.400 The most complicated uses involve antimicrobials 
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being used in or on food.401 These include uses such as: 
[The] treatment of raw agricultural commodities in a food processing 
facility [with antimicrobial agents]; [the] application of an 
antimicrobial agent to process water in a food processing facility and 
control a pest in the water (e.g., pulp and paperboard use, use in cane-
sugar and beet-sugar mills); [the] production of food packaging; [the] 
production of food contact articles other than food packaging; no 
intended effect on the surface of the article.402 
Sharing the regulation of bioengineered meats is not a new concept for the 
FDA, as the agency has regulated genetically engineered meats for decades.403 
An example of this is AquAdvantage Salmon, more commonly referred to as GE 
Salmon.404 Even though the IP rights tied to GE organisms are still being worked 
out in the courts,405 the GE Salmon model could parallel how the FDA and 
USDA share the responsibility of regulating cell-based meats.406 
To illustrate this point further, the executive branch’s biotechnology 
coordinated framework policy has played a large part in the United States’ 
bioengineered product regulation.407 Initially integrated in June 1986 as the 
Coordinated Framework for Regulation of Biotechnology, three agencies—the 
USDA, FDA, and EPA—would share the responsibility for implementation 
policies regarding biotechnology and recombinant DNA (“rDNA”) products.408 
Recombinant DNA are DNA sequences that have been artificially made by 
adding in a segment of DNA from one organism’s genome to another organism’s 
DNA sequence.409 Recombinant DNA products can be transgenic plants, 
                                                          
FEDERAL OR STATE AGENCY REQUIREMENTS (2020), https://www.epa.gov/pesticide-
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 404 See Matthew Morgan, The AquAdvantage Salmon: Who Owns Escaped Genetically 
Modified Animals?, 17 OCEAN & COASTAL L.J. 127, 137 (2011); see also Mark 
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21, 2015), https://blog.patentology.com.au/2015/11/patented-frankenfish-finally-
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 405 Morgan, supra note 404, at 138. 
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 407 John P. Holdren et al., supra note 398, at 2. 
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bacteria, or pesticides.410 These products are found widely in modern society.411 
The coordinated framework resolved jurisdictional disputes among the 
agencies over biotechnology products that fell within the jurisdiction of multiple 
agencies, and it established the basis for much of the rDNA and biotech 
regulation that exists today.412 In fact, “Since announcement of the coordinated 
framework, federal regulators have cleared the way for hundreds of new 
agricultural, health care, and industrial products, including dozens of plants 
modified through modern biotechnology.”413 For example, a policy that came 
out of the coordinated framework was that the USDA would “regulate plants 
grown to produce food or feed,” and the FDA “would have jurisdiction over the 
food or feed itself.”414 
However, plant issues and similar issues were not addressed in the 
coordinated framework.415 The coordinated framework left certain issues open, 
such as how to handle transgenic plants that were modified to resist disease and 
ward off insect pests because such plants technically fall under the jurisdiction 
of all three agencies.416 It took nearly fourteen years for the three agencies to 
finally come to a conclusion on how to regulate these cross-cutting issues with 
an update in 2000,417 and the agencies still needed to amend and update the 
coordinated framework again in 2017 to further resolve disputes over 
regulation.418 
Due to the decades-long disputes over jurisdictional issues that could not 
easily be solved, there were a number of delays in biotech and rDNA products 
coming to market.419 These errors and delays tied to multi-agency regulations 
can be minimized if agencies clearly state and focus on their individual missions, 
invite discussions at earlier stages, and promptly comply with their end of the 
coordinated framework.420 
In the future, a joint regulation between the FDA and the USDA over cell-
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based meats will give rise to similar jurisdictional disputes when these meat 
products attempt to come to market. These disputes could result in delays during 
the handoff of the approval process stage.421 For example, what constitutes a 
good manufacturing process and what constitutes harvesting may become points 
of contention under current FDA and USDA definitions.422 Thus, when a 
company submits its process, there may be some dispute as to whose job it is to 
give the approval and what exactly is approved.423 
Meanwhile, the patent for the company’s manufacturing process will continue 
to run while these jurisdictional issues are worked out between the FDA and the 
USDA. The Hatch-Waxman Act provides a good example for Congress to 
follow in authorizing the FDA to give cell-based meat producers an extension 
on their patents for both processes and cell lines while the companies are 
awaiting FDA approval.424 
One way to address time loss on a patent is Congress could allow for time to 
be added back to each of the company’s patents as an extension425 while the cell-
based meat manufacturers are awaiting FDA and USDA approval of the 
manufacturing process (collection stage, growth stage, and harvesting stage) and 
labeling requirements.426 Time could also be reduced for a lack of action on the 
part of the manufacturers so that active participation of the manufacturers can 
be ensured; the FDA could do this as it already has experience in this area.427 
The alternative to not having legislation that extends the length of patents on 
cell-based meats is relying on the general timeframe of the current patent 
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system.428 As of May 2017, the average pendency of a patent application is 
roughly thirty-three months,429 and right now, for drugs at least, approval takes 
about seven to twelve years.430 There is no indication that the approval process 
for a patent tied to cell-based meats will take that long, but it is safe to assume 
that it will take a year or more because of the backlog in other areas of the FDA, 
such as drugs and devices.431 Therefore, cell-based meat manufacturers are 
already looking at multiple years from the time of applying for a patent until 
they are able to reap the rewards and benefit from their innovations.432 
Even when using the fastest, most generous estimate of time, the approval of 
the patents and approval from the FDA and USDA will still take a substantial 
amount of time. This could amount to at least three years of earnings that these 
manufacturers will have to forfeit and which investors will not be able to recover 
their money from.433 
However, the shortened time, especially on the design patents, will help bring 
competitors into the market in a quicker way than if there were patent 
extensions.434 Design patents have an average pendency anywhere from thirteen 
months to nineteen months.435 If manufacturers could find a way to make design 
patents sufficient to protect their works, then this would increase the supply of 
cell-based meats brought to market.436 The increased supply generated from 
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competitors would then drive down costs.437 The biggest concern of the cell-
based meat market is the cost of the meats per pound; in 2019, it was estimated 
that the first meat product to market would cost about fifty dollars per pound.438 
This price is still much too high to even consider making a profit at this point.439 
However, in the same way generic drugs have driven down the price of brand 
drugs,440 other cell-based meat manufacturers looking to scale up manufacturing 
will cause the price of cell-based meats to drop.441 
Even though a reduced timeframe of patents on cell-based meat products by 
allowing the natural course of the patent to run would be beneficial to cost and 
efficiencies, it is hard to say if three, four, or even five years is enough of a 
reduction in time to see these benefits.442 Budding science still needs to attract 
market investors and manufacturers to the market.443 Without these investors 
and manufacturers, there would be no incentive to even consider reducing the 
cost or improving the efficiency of the growing process.444 
In addition, more competitors and investors would increase the 
experimentation of the processes and techniques used in the growth process.445 
This experimentation would help develop better manufacturing processes and 
more efficient collection, growth, and harvesting processes.446 This increased 
efficiency would also help drive down the cost of cell-based meat products and 
increase their availability to consumers.447 
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VII. CONCLUSION 
Strong patent protections allow for innovators and manufacturers to create 
and produce without the fear of being undercut or have their work stolen.448 
Also, strong patent protections incentivize investments in new technologies, 
thereby spurring newer, faster innovations.449 Currently, there is nothing more 
innovative than the science-fiction like cell-based meats.450 As this young area 
of food science is starting to bud, society needs to ensure that there are sufficient 
patent protections and incentives available to allow this market to find its 
niche.451 
Fortunately, Congress has already worked to protect areas of new and 
upcoming technology.452 Congress has experimented and has come to a 
reasonable solution in the world of drug development.453 Using the current drug 
regulatory sphere and the Hatch-Waxman Act as a framework, we can transpose 
that on the novel and innovative area of cell-based meats. 
The FDA and USDA will share regulatory oversight over the cell-based meat 
products.454 This joint regulatory oversight will come with delays due to the 
general approval process as well as jurisdictional questions.455 Therefore, 
Congress should consider giving back time on the cell-based meat patents due 
to these delays.456 This will allow for a fairer market and stronger protections 
for those companies manufacturing these meat products. 
Because the FDA already has the legal framework in place to handle both 
public health and patent challenges,457 Congress should use the patent extensions 
given to drug manufacturers in the Hatch-Waxman Act as a future legislative 
guide to give patent extensions to cell-based meat manufacturers.458 In doing so, 
Congress should give the FDA the responsibility of designating the time 
extension as well.459 This would allow for a smoother transition for the new act 
of Congress and, therefore, a more efficient process of giving the patent 
extensions to manufacturers seeking to enter the cell-based meat market. 
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